DANAMI-3-PRIMULTI Study
Conclusion DANAMI-3-PRIMULTI 10 years
The Third DANish Study of Optimal Acute Treatment of Patients With STEMI: PRImary PCI in MULTIvessel Disease – DANAMI-3—PRIMULTI
Description:
The goal of the trial was to compare the utility of infarct-related percutaneous coronary intervention (PCI) versus fractional flow reserve (FFR)-guided complete revascularization in patients presenting with ST-segment elevation myocardial infarction (STEMI) and evidence of multivessel disease.
The DANAMI-3—PRIMULTI study suggests that FFR-guided complete revascularization prior to hospital discharge is superior to culprit vessel only PCI in patients with multivessel disease presenting with STEMI and undergoing primary PCI.
Description:
The goal of the trial was to compare the utility of infarct-related percutaneous coronary intervention (PCI) versus fractional flow reserve (FFR)-guided complete revascularization in patients presenting with ST-segment elevation myocardial infarction (STEMI) and evidence of multivessel disease.
Complete revascularization guided by FFR in patients with STEMI and multivessel disease can
safely be performed and reduces the risk of future events – driven by revascularization
More than half of the patients experience recurrent myocardial infarction, revascularization,
or died
Complete revascularization may provide an absolute reduction of 13 events (-1 to 28 events)
per 100 persons
Interpretation:
The results of this trial indicate that, in patients with multivessel disease presenting with STEMI and undergoing successful primary PCI, FFR-guided multivessel PCI with a goal towards complete revascularization prior to hospital discharge is superior to culprit IRA only PCI. This study adds to the literature on multivessel PCI in patients with STEMI.